articleClinical Pharmacology & TherapeuticsJan 16, 2022BRONZE OA

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update

CRCraig R. LeeJAJasmine A. LuzumKSKatrin SangkuhlRSRoseann S. GammalMSMarc S. Sabatine

University of North Carolina at Chapel Hill · University of Michigan · +17 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

CYP2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 genotype impacts clopidogrel active metabolite formation. CYP2C19 intermediate and poor metabolizers who receive clopidogrel experience reduced platelet inhibition and increased risk for major adverse cardiovascular and cerebrovascular events. This guideline is an update to the 2013 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of clopidogrel based on CYP2C19 genotype and includes expanded indications for CYP2C19 genotype-guided antiplatelet therapy, increased strength of recommendation for CYP2C19 intermediate metabolizers, updated CYP2C19 genotype to phenotype translation, and evidence…

Citation impact

449
total citations
FWCI
66.88
Percentile
100%
References
47
Citations per year

Authors

17
  • CR
    Craig R. Lee

    University of North Carolina at Chapel Hill

  • JA
    Jasmine A. Luzum

    University of Michigan

  • KS
    Katrin Sangkuhl

    Stanford University

  • RS
    Roseann S. Gammal

    St. Jude Children's Research Hospital, Massachusetts College of Pharmacy and Health Sciences

  • MS
    Marc S. Sabatine

    Brigham and Women's Hospital, Harvard University, Thrombolysis in Myocardial Infarction Study Group

Topics & keywords

Topics
Keywords
  • Clopidogrel
  • CYP2C19
  • Guideline
  • Pharmacogenetics
  • Prodrug
  • Genotype
  • Active metabolite
  • Adverse effect
No related works found for this paper.

Funding